Improvement in migraine-specific quality of life in a clinical trial of rizatriptan

Cephalalgia

Volumn 17, Issue 8, 1997, Pages 867-872

  Santanello, N C ^a   Polis, A B ^a   Hartmaier, S L ^b   Kramer, M S ^a   Block, G A ^b   Silberstein, S D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Germantoim Hospital   (United States)

Author keywords

Health related quality of life; Migraine; Rizatriptan

Indexed keywords

ANTIMIGRAINE AGENT; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST;

ADULT; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 0031453675     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1708867.x     Document Type: Article

References (21)

1. Lipton RB, Stewart WF, Celentano DD, Reed ML. Underdiagnosed migraine headache: a comparison of symptombased and reported physician diagnosis. Arch Intern Med 1992;152:1273-8
2. Lipton RB, Stewart WF. Migraine in the United States: epidemiology and health care use. Neurology 1993;43 Suppl 3:6-10
3. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension type headache. Part II. Can J Neurol Sei 1992;19:333-9
4. Stang PE, Yanagihara T, Swanson JW, Beard CM, OTallon WM, Guess HA, et al. Incidence of migraine headache: a population-based study in Olmstead County, Minnesota. Neurology 1992;42:1657-62
5. Essink-Bot ML, van Royen L, Krabbe P, Bonsei GJ, Rutten FH. The impact of migraine on health status. Headache 1995; 35:200-6
6. Passchier J, de Boo M, Quaak HZ, Brienen JA. Health-related quality of life of chronic headache patients is predicted by emotional component of their pain. Headache 1996 6:556-60
7. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995 35:449-54
8. Dahlöf CGH. Health-related quality of life under six months' treatment of migraine-an open clinic-based longitudinal study. Cephalalgia 1995;15:414-22
9. Dahlöf CGH, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life between attacks. Cephalalgia 1995;15:31-6
10. Richard A, Henry P, Chazot G. Qualité de vie et migraine: validation du questionnaire Q V.M. en consultation hospitalière et en médecine générale. Thérapie 1993;48:89-96
11. Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD. Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 1995 5:320-9
12. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995;35:330-7
13. Wagner TH, Patrick DL, Galer BS, Berzon RA. A new instrument to assess the long-term effects from migraine: development and psychometric testing of the MSQOL. Headache 1996 6:484-92
14. Gijsman H, Kramer MS, Sargent J, Tuchman M, MatzuraWolfe D, Polis A, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997 (in press)
15. Tandon PK. Applications of global statistics in analyzing quality of life data. Stat Med 1990,-9:819-27
16. Hochberg. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2
17. Lipton RB. Health-related quality of life headache research. Headache 1995 35:447
18. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42:36-42
19. Mushet GR, Miller D, Clements B, Pait G, Gutterman DL. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996 36:137-43
20. Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996;28:171-7
21. Greiner DL, Addy SN. Sumatriptan use in a large groupmodel health maintenance organization. Am J Health Sust Pharm 1996p3:633-8